Cargando…
PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429669/ http://dx.doi.org/10.1097/01.HS9.0000975628.90605.7e |
| _version_ | 1785090770859982848 |
|---|---|
| author | Kuykendall, Andrew Bradley, Terrence Komrokji, Rami S. Berry, Tymara Dougherty, Souria Sherman, Laurie Peng, Lixian Huang, Fei Wan, Ying Rodolf, Vivian Ho, Judy Navada, Shyamala Mascarenhas, John |
| author_facet | Kuykendall, Andrew Bradley, Terrence Komrokji, Rami S. Berry, Tymara Dougherty, Souria Sherman, Laurie Peng, Lixian Huang, Fei Wan, Ying Rodolf, Vivian Ho, Judy Navada, Shyamala Mascarenhas, John |
| author_sort | Kuykendall, Andrew |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429669 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104296692023-08-17 PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF Kuykendall, Andrew Bradley, Terrence Komrokji, Rami S. Berry, Tymara Dougherty, Souria Sherman, Laurie Peng, Lixian Huang, Fei Wan, Ying Rodolf, Vivian Ho, Judy Navada, Shyamala Mascarenhas, John Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429669/ http://dx.doi.org/10.1097/01.HS9.0000975628.90605.7e Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Kuykendall, Andrew Bradley, Terrence Komrokji, Rami S. Berry, Tymara Dougherty, Souria Sherman, Laurie Peng, Lixian Huang, Fei Wan, Ying Rodolf, Vivian Ho, Judy Navada, Shyamala Mascarenhas, John PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF |
| title | PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF |
| title_full | PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF |
| title_fullStr | PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF |
| title_full_unstemmed | PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF |
| title_short | PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF |
| title_sort | pb2221: an open-label, phase 1/1b study to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of imetelstat in combination with ruxolitinib in patients with myelofibrosis: improvemf |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429669/ http://dx.doi.org/10.1097/01.HS9.0000975628.90605.7e |
| work_keys_str_mv | AT kuykendallandrew pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT bradleyterrence pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT komrokjiramis pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT berrytymara pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT doughertysouria pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT shermanlaurie pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT penglixian pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT huangfei pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT wanying pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT rodolfvivian pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT hojudy pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT navadashyamala pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf AT mascarenhasjohn pb2221anopenlabelphase11bstudytoevaluatethesafetypharmacokineticspharmacodynamicsandclinicalactivityofimetelstatincombinationwithruxolitinibinpatientswithmyelofibrosisimprovemf |